Rating
References
Examine impressive results for simple, uncomplicated clot prevention
See study designs and results for the rivaroxaban phase III studies
View the direct inhibition of Factor Xa, an active area of research
Thromboembolic disorders pose life threatening risks to millions of patients
Connect with a world of events devoted to thromboembolic research
Learn more about ‘Xarelto’ and Thrombosis by watching videos and using interactive tools
Desirable Characteristics of an Anticoagulant
Results of the Landmark RECORD Programme
History of Warfarin
Pooled Analysis of RECORD1, 2, and 3
Now Playing:
Widening the Gap Between Risk and Benefit
Related Videos:
The RECORD Programme
Reassuring Safety Profile of Xarelto
Xarelto® (rivaroxaban): The First Single-Drug Solution for VTE Treatment (Summary)
Xarelto® (rivaroxaban) is Highly Effective in Treating Acute DVT and Preventing Recurrent VTE
Xarelto® (rivaroxaban): A Single-Drug Solution for the Treatment of DVT, and Prevention of Recurrent DVT and PE
Xarelto Countdown
Mode of Action of ‘Xarelto’
Challenging the Burden of Mortality in ACS
Potential Health Economics Benefits of 'Xarelto'
Highly Effective Protection with Xarelto®
One-Tablet, Once-Daily Xarelto® Adds Simplicity to Stroke Prevention